Recipharm RECI B
This picture changes. Follow Recipharm free — email when the signal or risk changes + a Sunday weekly brief.
Follow Recipharm freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 2 Aug 2026
General analysis — not personal advice.
NEUTRAL
9/10
Confidence
No direct position possible; monitor IPO/exit 2026–2028 or indirect via EQT.
Delisted status with no direct market exposure keeps NEUTRAL signal appropriate despite stable operational progress in biologics.
Market sentiment
7/10
↑
Trend: Improving
Sentiment has improved modestly as the US capex signals demand and strategic focus in biologics/ATMP, but visibility in market data and social media remains low because the company is privately held.
Risk assessment
6/10
Dilution:
Low
Private and profitable; no equity raise signal
Jurisdiction:
Low
Mainly Sweden/Western Europe/US footprint
Execution:
Medium
Complex regulatory execution in biologics/ATMP
About the company
Recipharm is a CDMO providing pharmaceutical development and manufacturing services to pharma and biotech customers, with strengths in oral solid dose and sterile fill & finish. The company is privately owned (EQT) and delisted, meaning the shares are not publicly tradable. Latest available full-year information points to record 2024 revenue and continued portfolio focus plus investments in higher-margin capabilities.
Sector:
Pharmaceutical contract development and manufacturing (CDMO)
Type:
Industrial
Next report
20 Nov 2026
Q3
Catalysts
20 Aug 2026
Q2 2026 update (calendar milestone)
Medium
Q4 2026
HPAPI expansion in Spain
Medium
Unknown
CEPI-funded NMR project for RNA vaccine quality
Medium
Horizon:
Bull case
New contracts in biologics and ATMP can strengthen the growth narrative even as a private company.
Bear case
Limited transparency as a privately owned company increases uncertainty around execution and macro effects.
Signal rationale (informational)
Delisted status with no direct market exposure keeps NEUTRAL signal appropriate despite stable operational progress in biologics.
Recent news
- No new material news identified after 2026-07-02. The company remains privately owned following the 2021 EQT acquisition, limiting transparency.
Exchange
Stockholm
Type
Industrials
Sector
Pharmaceutical contract development and manufacturing (CDMO)
This picture changes. Follow Recipharm free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.